Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
Comparative economic analysis of B-cell maturation antigen-targeted bispecific antibodies in triple-class exposed relapsed/refractory multiple myeloma: linvoseltamab versus teclistamab and elranatamab.
Journal: Current medical research and opinion
Published: May 20, 2026
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.
Journal: Blood advances
Published: April 21, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.
Journal: Blood advances
Published: April 21, 2026
Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.
Journal: Bone marrow transplantation
Published: April 01, 2026
MRD in multiple myeloma: Moving from "minimal" to "measurable".
Journal: Blood reviews
Published: March 24, 2026
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma.
Journal: American journal of hematology
Published: February 20, 2026
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.
Journal: JCO clinical cancer informatics
Published: January 14, 2026
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.
Journal: Haematologica
Published: December 19, 2025
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.
Journal: Blood
Published: December 15, 2025
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.
Journal: Blood cancer journal
Published: November 04, 2025
Last Updated: 09/26/2026